Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety
Gang Wang,1 Xiumin You,2 Xueyi Wang,3 Xiufeng Xu,4 Ludong Bai,5 Jian Xie,6 Zhijian Yao,7 QiZhong Yi,8 Jun Ma,9 Jinan Wang,10 Jianmin Zhuo,11 Cuili Hu11 1Psychiatry Department, Beijing Anding Hospital, Capital Medical University, National Clinical Research Center for Mental Disorders, Beijing, China...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8cfb2087f7aa4e20b5bef4a44c0f4a04 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8cfb2087f7aa4e20b5bef4a44c0f4a04 |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
anxiety Chinese escitalopram major depressive disorder social function Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
anxiety Chinese escitalopram major depressive disorder social function Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Wang G You X Wang X Xu X Bai L Xie J Yao Z Yi Q Ma J Wang J Zhuo J Hu C Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety |
| description |
Gang Wang,1 Xiumin You,2 Xueyi Wang,3 Xiufeng Xu,4 Ludong Bai,5 Jian Xie,6 Zhijian Yao,7 QiZhong Yi,8 Jun Ma,9 Jinan Wang,10 Jianmin Zhuo,11 Cuili Hu11 1Psychiatry Department, Beijing Anding Hospital, Capital Medical University, National Clinical Research Center for Mental Disorders, Beijing, China; 2Psychiatry Department, Xianyue Hospital, Xiamen, China; 3Psychiatry Department, Institute of Mental Health of Hebei Medical University, Shijiazhuang, China; 4Psychiatry Department, Kunming Medical University Affiliated Hospital, Kunming, China; 5Psychiatry Department, Shangdong Province Mental Hospital, Jinan, China; 6Psychiatry Department, Hangzhou First People Hospital, Hangzhou, China; 7Psychiatry Department, Nanjing Brain Hospital, Nanjing, China; 8Psychiatry Department, Xinjiang University Affiliated First Hospital, Urumqi, China; 9Psychiatry Department, Inner Mongolia Mental Hospital, Hulun Buir, China; 10Medical Department, Lundbeck Pharmaceutical Information Consulting Co., Ltd., Beijing, China; 11Medical Department, Xi’an Janssen Pharmaceutical Ltd., Beijing, China Background: Anxiety symptoms usually worsen depression and functional impairment. The present study was aimed to evaluate the impact of escitalopram on social function and quality of life in major depressive disorder (MDD) patients with anxiety symptoms. Patients and methods: Adult MDD patients with functional impairment (Sheehan Disability Scale [SDS] score ≥9) and anxiety symptoms (Hamilton Anxiety Rating Scale [HAM-A] score ≥14) received escitalopram (10–20 mg/day) for 8 weeks. Symptom status was assessed by SDS, Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form, Montgomery-Åsberg Depression Rating Scale (MADRS), HAM-A, and Quick Inventory of Depressive Symptomatology-Self Report scales. Safety was evaluated by treatment-emergent adverse events (TEAEs). Results: Overall, 208 (79.7%) of 261 enrolled patients completed the 8-week treatment. Mean (SD) SDS and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form total scores were 17.4 (5.87) and 39.3 (14.43) at baseline, which improved to 7.6 (6.71) and 61.6 (15.80), respectively, at week 8. Totally, 59.2% of patients achieved functional remission (SDS≤6) and 61.7% of patients achieved depression remission (MADRS≤10) at week 8; 48.1% of patients achieved both functional and depression remission (SDS≤6 and MADRS≤10). The change in SDS total score was positively correlated with the change in MADRS and HAM-A total scores at each visit. Patient’s baseline SDS score was related with depression score (regression coefficient=0.40582, p=0.0005); remission of SDS was statistically related to a reduction of week 2 and week 6 HAM-A score (p<0.0001) and reduction of MADRS score (p<0.0001). Overall, 25.7% of patients reported ≥1 TEAEs. Most frequently reported TEAEs were nausea (5.8%), diarrhea (2.3%), and dizziness (2.7%). Most TEAEs were mild to moderate in severity. Four patients reported serious TEAEs, two patients reported suicide attempts, and one patient completed suicide. Conclusion: Escitalopram (10–20 mg/day) treatment was efficacious in reducing depression, improving social function, and quality of life in MDD patients with anxiety symptoms. No new safety signals were identified. Keywords: anxiety, Chinese, escitalopram, major depressive disorder, social function |
| format |
article |
| author |
Wang G You X Wang X Xu X Bai L Xie J Yao Z Yi Q Ma J Wang J Zhuo J Hu C |
| author_facet |
Wang G You X Wang X Xu X Bai L Xie J Yao Z Yi Q Ma J Wang J Zhuo J Hu C |
| author_sort |
Wang G |
| title |
Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety |
| title_short |
Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety |
| title_full |
Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety |
| title_fullStr |
Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety |
| title_full_unstemmed |
Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety |
| title_sort |
safety and effectiveness of escitalopram in an 8-week open study in chinese patients with depression and anxiety |
| publisher |
Dove Medical Press |
| publishDate |
2018 |
| url |
https://doaj.org/article/8cfb2087f7aa4e20b5bef4a44c0f4a04 |
| work_keys_str_mv |
AT wangg safetyandeffectivenessofescitalopraminan8weekopenstudyinchinesepatientswithdepressionandanxiety AT youx safetyandeffectivenessofescitalopraminan8weekopenstudyinchinesepatientswithdepressionandanxiety AT wangx safetyandeffectivenessofescitalopraminan8weekopenstudyinchinesepatientswithdepressionandanxiety AT xux safetyandeffectivenessofescitalopraminan8weekopenstudyinchinesepatientswithdepressionandanxiety AT bail safetyandeffectivenessofescitalopraminan8weekopenstudyinchinesepatientswithdepressionandanxiety AT xiej safetyandeffectivenessofescitalopraminan8weekopenstudyinchinesepatientswithdepressionandanxiety AT yaoz safetyandeffectivenessofescitalopraminan8weekopenstudyinchinesepatientswithdepressionandanxiety AT yiq safetyandeffectivenessofescitalopraminan8weekopenstudyinchinesepatientswithdepressionandanxiety AT maj safetyandeffectivenessofescitalopraminan8weekopenstudyinchinesepatientswithdepressionandanxiety AT wangj safetyandeffectivenessofescitalopraminan8weekopenstudyinchinesepatientswithdepressionandanxiety AT zhuoj safetyandeffectivenessofescitalopraminan8weekopenstudyinchinesepatientswithdepressionandanxiety AT huc safetyandeffectivenessofescitalopraminan8weekopenstudyinchinesepatientswithdepressionandanxiety |
| _version_ |
1718401565170073600 |
| spelling |
oai:doaj.org-article:8cfb2087f7aa4e20b5bef4a44c0f4a042021-12-02T03:54:08ZSafety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety1178-2021https://doaj.org/article/8cfb2087f7aa4e20b5bef4a44c0f4a042018-08-01T00:00:00Zhttps://www.dovepress.com/safety-and-effectiveness-of-escitalopram-in-an-8-week-open-study-in-ch-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Gang Wang,1 Xiumin You,2 Xueyi Wang,3 Xiufeng Xu,4 Ludong Bai,5 Jian Xie,6 Zhijian Yao,7 QiZhong Yi,8 Jun Ma,9 Jinan Wang,10 Jianmin Zhuo,11 Cuili Hu11 1Psychiatry Department, Beijing Anding Hospital, Capital Medical University, National Clinical Research Center for Mental Disorders, Beijing, China; 2Psychiatry Department, Xianyue Hospital, Xiamen, China; 3Psychiatry Department, Institute of Mental Health of Hebei Medical University, Shijiazhuang, China; 4Psychiatry Department, Kunming Medical University Affiliated Hospital, Kunming, China; 5Psychiatry Department, Shangdong Province Mental Hospital, Jinan, China; 6Psychiatry Department, Hangzhou First People Hospital, Hangzhou, China; 7Psychiatry Department, Nanjing Brain Hospital, Nanjing, China; 8Psychiatry Department, Xinjiang University Affiliated First Hospital, Urumqi, China; 9Psychiatry Department, Inner Mongolia Mental Hospital, Hulun Buir, China; 10Medical Department, Lundbeck Pharmaceutical Information Consulting Co., Ltd., Beijing, China; 11Medical Department, Xi’an Janssen Pharmaceutical Ltd., Beijing, China Background: Anxiety symptoms usually worsen depression and functional impairment. The present study was aimed to evaluate the impact of escitalopram on social function and quality of life in major depressive disorder (MDD) patients with anxiety symptoms. Patients and methods: Adult MDD patients with functional impairment (Sheehan Disability Scale [SDS] score ≥9) and anxiety symptoms (Hamilton Anxiety Rating Scale [HAM-A] score ≥14) received escitalopram (10–20 mg/day) for 8 weeks. Symptom status was assessed by SDS, Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form, Montgomery-Åsberg Depression Rating Scale (MADRS), HAM-A, and Quick Inventory of Depressive Symptomatology-Self Report scales. Safety was evaluated by treatment-emergent adverse events (TEAEs). Results: Overall, 208 (79.7%) of 261 enrolled patients completed the 8-week treatment. Mean (SD) SDS and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form total scores were 17.4 (5.87) and 39.3 (14.43) at baseline, which improved to 7.6 (6.71) and 61.6 (15.80), respectively, at week 8. Totally, 59.2% of patients achieved functional remission (SDS≤6) and 61.7% of patients achieved depression remission (MADRS≤10) at week 8; 48.1% of patients achieved both functional and depression remission (SDS≤6 and MADRS≤10). The change in SDS total score was positively correlated with the change in MADRS and HAM-A total scores at each visit. Patient’s baseline SDS score was related with depression score (regression coefficient=0.40582, p=0.0005); remission of SDS was statistically related to a reduction of week 2 and week 6 HAM-A score (p<0.0001) and reduction of MADRS score (p<0.0001). Overall, 25.7% of patients reported ≥1 TEAEs. Most frequently reported TEAEs were nausea (5.8%), diarrhea (2.3%), and dizziness (2.7%). Most TEAEs were mild to moderate in severity. Four patients reported serious TEAEs, two patients reported suicide attempts, and one patient completed suicide. Conclusion: Escitalopram (10–20 mg/day) treatment was efficacious in reducing depression, improving social function, and quality of life in MDD patients with anxiety symptoms. No new safety signals were identified. Keywords: anxiety, Chinese, escitalopram, major depressive disorder, social functionWang GYou XWang XXu XBai LXie JYao ZYi QMa JWang JZhuo JHu CDove Medical PressarticleanxietyChineseescitaloprammajor depressive disordersocial functionNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 2087-2097 (2018) |